摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-phenethyl-2H-pyrazole-3-carbaldehyde | 956723-13-0

中文名称
——
中文别名
——
英文名称
2-phenethyl-2H-pyrazole-3-carbaldehyde
英文别名
2-(2-phenylethyl)pyrazole-3-carbaldehyde
2-phenethyl-2H-pyrazole-3-carbaldehyde化学式
CAS
956723-13-0
化学式
C12H12N2O
mdl
——
分子量
200.24
InChiKey
GNKMLUZRQKOBEF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    34.9
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors
    摘要:
    The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.
    DOI:
    10.1016/j.bmcl.2008.04.020
  • 作为产物:
    描述:
    1-苯乙基-1H-吡唑正丁基锂N,N-二甲基甲酰胺氯化铵 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 3.0h, 以43%的产率得到2-phenethyl-2H-pyrazole-3-carbaldehyde
    参考文献:
    名称:
    FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE
    摘要:
    这项发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括该发明中化合物的药物组合物。该发明还提供了用于治疗和预防神经系统疾病,如神经精神病和神经退行性疾病,以及疼痛、共济失调和抽搐的方法。该发明中的化合物具有一般结构:其中A为NH或S。Q是从CR1和N中选择的成员。X和Y分别是从O、S、CR2、N和NH中独立选择的成员。R1、R2和R4是从H和F中独立选择的成员,前提是至少选择R1、R2和R4中的一个成员为F。R6是从O−X+和OH中选择的成员,其中X+是正离子,从无机正离子和有机正离子中选择的成员。
    公开号:
    US20080004327A1
点击查看最新优质反应信息

文献信息

  • Fused heterocyclic inhibitors of D-amino acid oxidase
    申请人:Heffernan L. R. Michele
    公开号:US20080058395A1
    公开(公告)日:2008-03-06
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein Q is a member selected from O, S, CR 1 and N, X and Y are members independently selected from CR 2 , O, S, N and NR 3 .
    本发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括该发明化合物的制药组合物。同时,还提供了治疗和预防神经系统疾病,如神经精神疾病和神经退行性疾病,以及疼痛、共济失调和惊厥的方法。该发明化合物具有以下一般结构:其中Q是从O、S、CR1和N中选择的成员,X和Y是独立选择自CR2、O、S、N和NR3的成员。
  • Fluoro-substituted inhibitors of D-amino acid oxidase
    申请人:Sepracor Inc.
    公开号:US07884124B2
    公开(公告)日:2011-02-08
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O−X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.
    本发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括本发明化合物的制药组合物。本发明还提供了用于治疗和预防神经系统疾病,如神经精神疾病和神经退行性疾病,以及疼痛、共济失调和抽搐的方法。本发明化合物具有以下一般结构: 其中A为NH或S。Q为选择自CR1和N的成员。X和Y是独立选择自O、S、CR2、N和NH的成员。R1、R2和R4是独立选择自H和F的成员,但至少选择自R1、R2和R4中的一个成员为F。R6为选择自O−X+和OH的成员,其中X+为正离子,其为选择自无机正离子和有机正离子的成员。
  • US7884124B2
    申请人:——
    公开号:US7884124B2
    公开(公告)日:2011-02-08
  • [EN] FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES FUSIONNÉS DE LA D-AMINOACIDE-OXYDASE
    申请人:SEPRACOR INC
    公开号:WO2008005456A2
    公开(公告)日:2008-01-10
    [EN] This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure wherein Q is a member selected from O, S, CR1 and N, X and Y are members independently selected from CR2, O, S, N and NR3.
    [FR] La présente invention concerne des inhibiteurs innovants de l'enzyme D-aminoacide-oxydase ainsi que des compositions pharmaceutiques qui comprennent les composés de l'invention. L'invention concerne également des procédés de traitement et de prévention de troubles neurologiques, tels que des maladies neuropsychiatriques et neurodégénératives, de même que de la douleur, de l'ataxie et des convulsions. Les composés selon l'invention présentent la structure générale dans laquelle Q est choisi parmi O, S, CR1 et N, X et Y sont choisis indépendamment parmi CR2, O, S, N et NR3.
  • FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE
    申请人:Heffernan L. R. Michele
    公开号:US20080004327A1
    公开(公告)日:2008-01-03
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR 1 and N. X and Y are members independently selected from O, S, CR 2 , N and NH. R 1 , R 2 and R 4 are members independently selected from H and F, provided that at least one member selected from R 1 , R 2 and R 4 is F. R 6 is a member selected from O − X + and OH, wherein X + is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.
    这项发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括该发明中化合物的药物组合物。该发明还提供了用于治疗和预防神经系统疾病,如神经精神病和神经退行性疾病,以及疼痛、共济失调和抽搐的方法。该发明中的化合物具有一般结构:其中A为NH或S。Q是从CR1和N中选择的成员。X和Y分别是从O、S、CR2、N和NH中独立选择的成员。R1、R2和R4是从H和F中独立选择的成员,前提是至少选择R1、R2和R4中的一个成员为F。R6是从O−X+和OH中选择的成员,其中X+是正离子,从无机正离子和有机正离子中选择的成员。
查看更多